How does Novo Nordisk's revenue cost control compare between 2022 and 2024?

Novo Nordisk's revenue cost control has shown improvement between 2022 and 2024, as evidenced by the increase in total revenue and a slight improvement in cost of goods sold (COGS) as a percentage of revenue. 1. **Total Revenue Increase**: The total revenue for Novo Nordisk has grown from $25.46 billion in 2022 to $40.31 billion in 2024, indicating a robust growth in sales and market performance. 2. **Cost of Goods Sold (COGS) Trend**: The COGS has also increased from $4.09 billion in 2022 to $6.18 billion in 2024. However, the COGS as a percentage of revenue has shown a slight improvement, from 16.08% in 2022 to 15.33% in 2024. This suggests that while the absolute cost of goods sold has increased, it has done so at a slower rate than revenue, leading to a more efficient cost control. |code|Ticker|Name|Date|Total Revenue (FY)|Cost of Goods Sold (FY)|market_code| |---|---|---|---|---|---|---| |NVO|NVO.N|Novo Nordisk|2022|2.545587869814E10|4.09241292768E9|169| |NVO|NVO.N|Novo Nordisk|2023|3.446622477057E10|5.30732464305E9|169| |NVO|NVO.N|Novo Nordisk|2024|4.030799738463E10|6.17966294962E9|169| In conclusion, Novo Nordisk has demonstrated effective cost control as reflected by the improvement in COGS as a percentage of revenue, despite the overall increase in COGS and revenue. This indicates a strong financial management and operational efficiency on the part of the company.